Monitor for upcoming clinical data readouts from the NuTide:701 Phase 2 study of NUC-7738, which would be a more material catalyst than this patent grant. The cash runway into 2029 reduces near-term dilution risk.
Price Chart
Executive Summary
NuCana announced that the European Patent Office granted a composition-of-matter patent (EP 3683225) for its anti-cancer candidate NUC-7738, adding to a global estate of over 85 issued patents. The patent strengthens long-term IP protection for NUC-7738, which is in Phase 2 testing for PD-1 inhibitor-resistant metastatic melanoma. The company also stated cash resources are expected to fund operations into 2029.
Key Facts
- European Patent Office granted composition-of-matter patent EP 3683225 for NUC-7738.
- NUC-7738 is protected by over 85 issued patents worldwide.
- NUC-7738 is in the Phase 2 part of a Phase 1/2 study (NuTide:701) in combination with Keytruda (pembrolizumab) for PD-1 inhibitor-resistant metastatic melanoma.
- Cash resources expected to fund planned operations into 2029.
- Similar composition-of-matter patents previously granted in the United States and China.
Financial Impact
No financial figures disclosed; patent grant is an IP milestone with no immediate revenue or cost impact.
Risk Factors
- Clinical-stage biotech with no approved products; NUC-7738 may fail in Phase 2 trials.
- Patent grant does not change the fundamental risk of clinical failure or regulatory denial.
- Cash runway into 2029 is a forward-looking statement and depends on operational assumptions.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-408365 |
| Document: d285861d6k.htm | 0001193125-26-408365 |
| Document: 0001193125-26-408365-index-headers.html | 0001193125-26-408365 |
| Document: 0001193125-26-408365-index.html | 0001193125-26-408365 |
| Document: 0001193125-26-408365.txt | 0001193125-26-408365 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $1.35 | awaiting T+60 | — | $1.04 (−22.96%) |
Jun 8, 2026 20w ago | 6-K | $2.05 $1.38 | ▼ −32.68% | ▼ −35.73% | $1.04 (−49.27%) |
Jun 1, 2026 21w ago | 6-K | $2.17 $1.47 | ▼ −32.26% | ▼ −33.49% | $1.04 (−52.07%) |
May 14, 2026 23w ago | 6-K | $2.18 $1.44 | ▼ −33.95% | ▼ −38.46% | $1.04 (−52.29%) |
May 6, 2026 24w ago | 6-K | $2.09 $1.35 | ▲ +35.41% | ▲ +39.24% | $1.04 (+50.24%) |
Mar 19, 2026 31w ago | Press Release | $1.65 $1.92 | ▲ +16.36% | ▲ +1.94% | $1.04 (−36.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers